• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·India·Healthcare·GLHRL.BO
Share

Global Longlife Hospital and Research Limited Stocks

₹ 13.4Last Updated 16.10.2026

Issuer Rating

3/7
Performance

Average

Risk

High

Recommendation

Sell

Market Cap

₹ 1.36M

₹ 13.4
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Global Longlife Hospital & Research Ltd. operates as a comprehensive tertiary healthcare provider, offering a wide array of specialized medical services. The institution facilitates medical professionals by providing the essential environment and resources needed for patient treatment. Its clinical departments include, but are not limited to, acute care and emergency services, immunology and allergy, anesthesiology, bariatric procedures, burn treatment, cancer care, cardiology and vascular surgery, intensive critical care, advanced dental work and implants, as well as diabetes and endocrinology management. The company was established on January 20, 2012, and is headquartered in Ahmedabad, India.

Company Valuation

Greatly undervalued
7/7

Based on key historical and expected multiples, the stock is greatly undervalued relative to its peers. In particular, the stock is 'cheap' on EV/EBITDA.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

19.10.2026 11:10

Big Tech Held Hostage: How the Worst-Case Scenario with CoreWeave Might Unfold

19.10.2026 10:47

Top Stories This Morning: Fears of a Crisis in Europe; Treasuries Regain Their Status as a Safe Haven

19.10.2026 10:31

Tesla and Meta Earnings Reports, PMI Data in the U.S. and Europe: What Investors Can Expect This Week

19.10.2026 09:39

The euro fell amid protests in France and geopolitical tensions

18.10.2026 21:01

IPO roundup: Anthropic valuation falls, SpaceX lifts space-sector investment

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026